Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. April 2026 19:15 ET | Quelle: F. Hoffmann-La Roche Ltd

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple...
21. April 2026 17:05 ET | Quelle: ABB Electrification

New 34.5kV HiPerGuard UPS: direct grid connection cuts AI data center power costs

Washington, D.C., USA, April 21, 2026 (GLOBE NEWSWIRE) -- ABB’s microgrid-ready UPS architecture integrates battery storage, renewables, and gas generation for resilience and flexibility for AI data...
21. April 2026 16:15 ET | Quelle: 21Shares

21shares Announces Staking Distribution Schedule for TDOT and TSUI

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- 21shares, one of the world’s largest issuers of cryptocurrency exchange traded products (ETPs), today announced its expected distribution dates of...
21. April 2026 11:45 ET | Quelle: F. Hoffmann-La Roche Ltd

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous...
21. April 2026 09:08 ET | Quelle: 21Shares

21Shares AG (the Issuer): Publication of UK Base Prospectus

21Shares AG LEI: 254900UWHMJRRODS3Z64 21 April 2026 Publication of Base Prospectus The following Base Prospectus has been approved by the Financial Conduct Authority and is available for...